12 Month Anniversary for Striate+, page-60

Management, not unlike heaps of other Aussie bio-techs, are very slow to progress clinical and regulatory success into commercial returns - C-19 aside. I am happily building for the long-term and look at times like this as a buying opportunity (but have fortunately had other winners to do so). ATI remains a superior product that will not be surpassed at a biological level, and CelGro has so much merit. This lot are a bit slack, communication is at times terrible, but they've (slowly) achieved regulatory success and will slowly do so commercially (or who knows even pull a De Puy [J&J] partnership out of the bag yet, given the ATI trial results).

If you think we are frustrated, I imagine Professor M.H. Zheng (Chief Scientific Officer) must be furious. He has orchestrated these brilliant products and the fruition of his life's hard work still yet to be achieved via large scale patient treatment, that would in return provide us with commercial and share return success.